Breast Cancer, Drugs | featured news

The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumor cells while sparing healthy ones. The drug Kadcyla (kad-SY'-luh) from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a double-shot of anti-tumor poison.

If you want the FDA to approve more innovative, new drugs based on promising but early clinical results, you have to give the FDA a way to revoke those approvals later on, should larger trials prove that those drugs aren't as safe or effective as they first seemed. This is why the FDA should be congratulated for the way it has handled the Avastin breast cancer saga, and why I hope we will see the FDA handle more cases like this one, not less.

The breast cancer drug Herceptin increases the risk of heart problems in elderly patients, especially those with a history of heart disease and/or ...

Federal health regulators have concerns about bladder and breast cancer seen in patients taking an experimental diabetes pill from Bristol-Myers ...

Doctors and patients have a new tool to prevent breast cancer: A drug that is already approved for the treatment of the disease.